Long-term outcomes of accelerated BEP (bleomycin, etoposide, cisplatin) for advanced germ cell tumours: updated analysis of an Australian multicentre phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)-Reference-Cited by-同舟云学术

Long-term outcomes of accelerated BEP (bleomycin, etoposide, cisplatin) for advanced germ cell tumours: updated analysis of an Australian multicentre phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)

Published:2016-12 Issue:12 Volume:27 Page:2302-2303
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Lawrence N.,Martin A.,Toner G.,Stockler M.,Buizen L.,Thomson D.,Gebski V.,Friedlander M.,Yeung A.,Wong N.,Gurney H.,Rosenthal M.,Singhal N.,Kichenadasse G.,Wong S.,Lewis C.,Vasey P.,Grimison P.

Funder

Cancer Council New South Wales, Cancer Council Victoria, Cancer Council Queensland, and Cancer Council South Australia

Cancer Australia and Cancer Institute New South Wales

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/27/12/2302/8622996/mdw313.pdf

Reference3 articles.

1. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group;J Clin Oncol,1997

2. Accelerated BEP for metastatic germ cell tumours: a multicenter phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP);Grimison;Ann Oncol,2014

3. Accelerated BEP: a phase I trial of dose-dense BEP for intermediate and poor prognosis metastatic germ cell tumour;Rimmer;Br J Cancer,2011

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Protocol for the P3BEP trial (ANZUP 1302): an international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours;BMC Cancer;2018-08-29